Inventage Lab said Sunday it will present research demonstrating its proprietary IVL-GeneFluidic® platform for large-scale manufacturing of mRNA lipid nanoparticles (mRNA-LNPs) at the CRS 2026 Annual Meeting & Exposition, one of the world’s leading conferences on drug delivery technologies.
The Controlled Release Society (CRS) conference, held July 6-9 in Lisbon, Portugal, will feature research on next-generation drug delivery technologies, including long-acting injectables (LAIs), mRNA, nucleic acid therapeutics and nanomedicine.
The research was supported by South Korea’s Ministry of Trade, Industry and Energy through its vaccine materials and manufacturing technology advancement program.
Inventage Lab said the study demonstrated that its proprietary microfluidics-based IVL-GeneFluidic® platform and HANDYGENE™ manufacturing systems can consistently produce high-quality LNP-based nucleic acid therapeutics from early research through commercial-scale manufacturing.
The company said it validated an in-line dilution process that reduces solvent concentration during LNP formation, enabling particle size and uniformity to remain stable even as production scales up.
Inventage Lab said the findings are significant because they demonstrate the potential for locally developed manufacturing systems to replace imported equipment currently used to produce LNP-based gene therapies and vaccines.
The company added that the platform could strengthen domestic commercialization, technology licensing and supply chain capabilities.
According to the study, the platform produced uniformly sized LNPs that were smaller than those generated using conventional methods across multiple RNA formats, including linear mRNA, self-amplifying RNA (saRNA) and circular mRNA.
The particle characteristics remained consistent from laboratory-scale production through commercial-scale manufacturing, while production yields reached as high as 89%.
Animal studies also showed comparable immune responses regardless of production scale, the company said.
Inventage Lab further reported that consistent manufacturing performance was confirmed across its entire production lineup, from the research-scale HANDYGENE™-LAB system to HANDYGENE™-GMP and HANDYGENE™-Commercial platforms.
The company said the results suggest manufacturing processes developed during research could be transferred directly to commercial production without additional process modifications.
“Our study validates our platform vision of ‘One Process. One Platform. Any RNA, Any Scale’ on the global stage,” an Inventage Lab official said. “We plan to strengthen customized commercialization and technology transfer capabilities while expanding partnerships with global pharmaceutical companies.”
The research was funded through the Ministry of Trade, Industry and Energy’s vaccine materials and manufacturing technology advancement program.
Separately, Inventage Lab is developing IVL3003, a once-monthly long-acting injectable candidate for Alzheimer’s disease.
According to the company, pharmacokinetic data showed the candidate reached peak blood concentration approximately two weeks after administration, maintained stable plasma levels and retained therapeutic concentrations beyond four weeks, supporting its potential as a long-acting formulation.